CSF3 and chronic myelogenous leukemia, BCR-ABL1 positive: Clinically, HHT have exhibit efficient inhibition activity against acute myelocytic leukemia (AML)30, 31 and chronic myeloid leukemias (CML)32, 33 alone or combined with granulocyte colony-stimulating factor, cytarabine, or interferon-α.